Real world predictors of hypogammaglobulinemia and serious infections in patients receiving ocrelizumab or ofatumumab for the treatment of multiple sclerosis: The REPLACE-MS study
Kiranpal Singh Sangha(University of Cincinnati), Ahmed Z Obeidat(Medical College of Wisconsin), Collin Jakubecz(University Hospitals of Cleveland), Aram Zabeti(University of Washington), Sara Esmaeili(Tarbiat Modares University), Sophia Woodson(University Hospitals of Cleveland), Hesham Abboud(University Hospitals of Cleveland), Alessandro Serra(University Hospitals Cleveland Medical Center), R. Hernandez(The University of Texas Southwestern Medical Center), Michelle Maynard(Froedtert Hospital)
Cited by 1
Related Papers
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers
|Cancer Discovery|2018|397
Postconditioning via stuttering reperfusion limits myocardial infarct size in rabbit hearts: role of ERK1/2
|American Journal of Physiology-Heart and Circulatory Physiology|2005|199
Aging Mouse Hearts Are Refractory to Infarct Size Reduction With Post-Conditioning
|Journal of the American College of Cardiology|2008|126
Cardioprotection with Postconditioning: Loss of Efficacy in Murine Models of Type-2 and Type-1 Diabetes
|Antioxidants and Redox Signaling|2010|123